Lilly and Entos Pharmaceuticals Enter into Research and Collaboration Agreement to Support the Development of Innovative Therapies in Multiple Neurologic Indications

Combination of Entos' Fusogenix nucleic acid delivery technology and Lilly's therapeutic cargo offers potential to overcome a key challenge in delivering nucleic acid therapies to the nervous system INDIANAPOLIS and EDMONTON, AB , Jan. 6, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) has